161 related articles for article (PubMed ID: 38147732)
21. Time Course of Changes in Sorafenib-Treated Hepatocellular Carcinoma Cells Suggests Involvement of Phospho-Regulated Signaling in Ferroptosis Induction.
Werth EG; Rajbhandari P; Stockwell BR; Brown LM
Proteomics; 2020 May; 20(10):e2000006. PubMed ID: 32336023
[TBL] [Abstract][Full Text] [Related]
22. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
23. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
24. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
25. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
[TBL] [Abstract][Full Text] [Related]
26. Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1α to inhibit apoptosis.
Gao Z; Wang D; Yang J; Li M; Ling C; Lv D; Cao Y; Chen Z; Shi C; Shen H; Tang Y
Biomed Pharmacother; 2023 Jul; 163():114750. PubMed ID: 37087978
[TBL] [Abstract][Full Text] [Related]
27. Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy.
Yu Y; Shen X; Xiao X; Li L; Huang Y
Small; 2023 Sep; 19(36):e2301149. PubMed ID: 37165608
[TBL] [Abstract][Full Text] [Related]
28. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
29. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
[TBL] [Abstract][Full Text] [Related]
30. CPLX2 Regulates Ferroptosis and Apoptosis Through NRF2 Pathway in Human Hepatocellular Carcinoma Cells.
Li H; Zhao J; Zhong XL; Xu PY; Du LJ; Fang P; Tan LJ; Li MJ; Zhang CF; Cao TS
Appl Biochem Biotechnol; 2023 Jan; 195(1):597-609. PubMed ID: 36107387
[TBL] [Abstract][Full Text] [Related]
31. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
[TBL] [Abstract][Full Text] [Related]
32. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
33. Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.
Su Y; Zhang Z; Lee LTO; Peng L; Lu L; He X; Zhang X
Adv Healthc Mater; 2023 Jan; 12(6):e2202663. PubMed ID: 36653312
[TBL] [Abstract][Full Text] [Related]
34. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Chen Z; Yuan T; Yan F; Ye S; Xie Q; Zhang B; Lin N; He Q; Yang B; Zhu H
BMC Cancer; 2022 Apr; 22(1):425. PubMed ID: 35440025
[TBL] [Abstract][Full Text] [Related]
35. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
36. Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.
Wei S; Wei F; Li M; Yang Y; Zhang J; Li C; Wang J
Biomed Pharmacother; 2023 Jul; 163():114798. PubMed ID: 37121146
[TBL] [Abstract][Full Text] [Related]
37. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
Zhang L; Li XM; Shi XH; Ye K; Fu XL; Wang X; Guo SM; Ma JQ; Xu FF; Sun HM; Li QQ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2023 Mar; 44(3):622-634. PubMed ID: 36109580
[TBL] [Abstract][Full Text] [Related]
39. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms.
Dahiya M; Dureja H
J Chemother; 2022 Sep; 34(5):286-301. PubMed ID: 34291704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
